Peter J. Reddig

Array ( [id] => 19130666 [patent_doc_number] => 20240136019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => SEQUENCING POLYCLONAL ANTIBODIES DIRECTLY FROM SINGLE PARTICLE CRYOEM DATA [patent_app_type] => utility [patent_app_number] => 18/547705 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11424 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18547705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748247 [patent_doc_number] => 20220226450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/665117 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17611518 [patent_doc_number] => 20220153797 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => METHODS OF TREATING CANCERS WITH CT45 TARGETED THERAPIES [patent_app_type] => utility [patent_app_number] => 17/649200 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17649200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093150 [patent_doc_number] => 20220411491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ANTIBODIES BINDING TO GPRC5D [patent_app_type] => utility [patent_app_number] => 17/586984 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19684042 [patent_doc_number] => 20250002587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/274118 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432883 [patent_doc_number] => 20240301381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ACE2-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/261854 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067291 [patent_doc_number] => 20240101717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => ANTI-HER-2/TROP-2 CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/273509 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19404924 [patent_doc_number] => 20240288435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => METHOD FOR PREDICTING RISK FOR THROMBOSIS IN CANCER PATIENT USING SOLUBLE CLEC2 [patent_app_type] => utility [patent_app_number] => 18/261155 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6611 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19112680 [patent_doc_number] => 20240124430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => PHARMACEUTICAL COMPOSITION FOR AMELIORATING MALIGNANT DISEASES [patent_app_type] => utility [patent_app_number] => 18/268434 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18268434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953662 [patent_doc_number] => 20240041989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => STRUCTURE-BASED DESIGN AND DISCOVERY OF LONG-ACTING COCAINE HYDROLASE MUTANTS WITH IMPROVED BINDING AFFINITY TO NEONATAL FC RECEPTOR FOR TREATMENT OF SUBSTANCE USE DISORDERS AND ORGANOPHOSPHORUS TOXICITY [patent_app_type] => utility [patent_app_number] => 18/268575 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18268575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345239 [patent_doc_number] => 20240254202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => LLAMA-DERIVED NANOBODIES BINDING THE SPIKE PROTEIN OF NOVEL CORONAVIRUS SARS-COV-2 WITH NEUTRALIZING ACTIVITY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/269156 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19564763 [patent_doc_number] => 12139524 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Immune cell compositions and methods of use [patent_app_type] => utility [patent_app_number] => 17/557607 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 77 [patent_no_of_words] => 44642 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17557607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003650 [patent_doc_number] => 20240067721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => NANOBODY TO GLYCOPROTEIN VI [patent_app_type] => utility [patent_app_number] => 18/269308 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13449 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18269308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792113 [patent_doc_number] => 20220251204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => BISPECIFIC BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/550219 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837803 [patent_doc_number] => 20220275108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE [patent_app_type] => utility [patent_app_number] => 17/545420 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460318 [patent_doc_number] => 20220073623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/535898 [patent_app_country] => US [patent_app_date] => 2021-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17535898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426798 [patent_doc_number] => 20220054506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => IMMUNOREGULATORY AGENT [patent_app_type] => utility [patent_app_number] => 17/521335 [patent_app_country] => US [patent_app_date] => 2021-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17521335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627308 [patent_doc_number] => 20220162323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/507138 [patent_app_country] => US [patent_app_date] => 2021-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19397132 [patent_doc_number] => 12071480 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-27 [patent_title] => CD47 antibodies and uses thereof for treating cancer [patent_app_type] => utility [patent_app_number] => 17/505911 [patent_app_country] => US [patent_app_date] => 2021-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 98 [patent_no_of_words] => 44935 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17505911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20920865 [patent_doc_number] => 12715913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-25 [patent_title] => Antibody against human thymic stromal lymphopoietin, method and application [patent_app_type] => utility [patent_app_number] => 18/252146 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4631 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 228 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252146 [rel_patent_id] =>[rel_patent_doc_number] =>)